Takahisa Yano
Overview
Explore the profile of Takahisa Yano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
690
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Onita T, Ishihara N, Yano T
Antibiotics (Basel)
. 2025 Jan;
14(1).
PMID: 39858377
Antimicrobial resistance (AMR) poses a critical global health threat, necessitating the optimal use of existing antibiotics. Pharmacokinetic/pharmacodynamic (PK/PD) principles provide a scientific framework for optimizing antimicrobial therapy, particularly to respond...
2.
Karino S, Usuda H, Kanda S, Okamoto T, Niibayashi T, Yano T, et al.
Biochem Biophys Rep
. 2024 Nov;
40:101848.
PMID: 39498441
This study investigated whether a standard calorie diet that is high in glucose and deficient in dietary fibre (described as HGD [high glucose diet]) induces hepatic fat accumulation in mice....
3.
Onita T, Nakamura K, Nishikawa G, Ishihara N, Tamaki H, Yano T, et al.
J Clin Pharmacol
. 2024 Aug;
PMID: 39183683
This study aimed to develop a prostatic pharmacokinetic model of ceftazidime and suggest more effective dosing strategy for the bacterial prostatitis, based on a site-specific pharmacokinetic and pharmacodynamic perspective. Subjects...
4.
Onita T, Ikawa K, Ishihara N, Tamaki H, Yano T, Naora K, et al.
Antibiotics (Basel)
. 2023 Feb;
12(2).
PMID: 36830214
This study aimed to assess the dosing regimens of ampicillin/sulbactam for pneumonia based on pulmonary pharmacokinetic (PK)/pharmacodynamic (PD) target attainment. Using the literature data, we developed pulmonary PK models and...
5.
Onita T, Ishihara N, Ikebuchi A, Yano T, Nishimura N, Tamaki H, et al.
J Clin Pharm Ther
. 2022 Jul;
47(12):2041-2048.
PMID: 35893441
What Is Known And Objective: Linezolid (LZD) may cause thrombocytopenia, which can result in discontinuation of treatment. In this study, the blood LZD trough concentration was estimated based on population...
6.
Pharmacodynamic Evaluation of Ampicillin-sulbactam in Pediatric Patients Using Plasma and Urine Data
Onita T, Ikawa K, Ishihara N, Tamaki H, Yano T, Naora K, et al.
Pediatr Infect Dis J
. 2022 Feb;
41(5):411-416.
PMID: 35195566
Background: We aimed to develop population pharmacokinetic (PK) models of ampicillin and sulbactam using pooled data analysis and to optimize dosing regimens of ampicillin-sulbactam (combination ratio of 2:1) in pediatric...
7.
Onita T, Ishihara N, Yano T, Nishimura N, Tamaki H, Ikawa K, et al.
Yakugaku Zasshi
. 2021 Mar;
141(3):441-445.
PMID: 33642514
Herein, we describe a case of an elderly patient with muscular dystrophy for whom control of the plasma vancomycin (VCM) concentration proved difficult when he developed a catheter-related bloodstream infection....
8.
Onita T, Ikawa K, Nakamura K, Nishikawa G, Kobayashi I, Ishihara N, et al.
J Clin Pharmacol
. 2020 Dec;
61(6):820-831.
PMID: 33314138
This study aims to define the penetration of ampicillin and sulbactam into prostate tissue, develop a prostatic pharmacokinetic model of each drug, and assess the appropriateness of ampicillin-sulbactam regimens for...
9.
Ishihara N, Nishimura N, Ikawa K, Karino F, Miura K, Tamaki H, et al.
Antibiotics (Basel)
. 2020 Mar;
9(3).
PMID: 32155905
The aim of this study was to develop a population pharmacokinetic model for piperacillin (PIPC)/tazobactam (TAZ) in late elderly patients with pneumonia and to optimize the administration planning by applying...
10.
Fukuda H, Yano T, Shimono N
Pharmacoeconomics
. 2018 Jul;
36(11):1367-1376.
PMID: 30022364
Background: Hospital-onset Clostridium difficile infections (CDIs) have a considerable clinical and economic impact on patients and payers. Quantifying the economic impact of CDIs can guide treatment strategies. However, previous studies...